REFERENCES
- Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. C.A. Cancer J. Clin. 2007; 57: 43–46
- Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131–1135
- Pittas A. G., Adler M., Fazzari M., et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 2000; 10: 261–268
- Wang W., Larson S. M., Fazzari M., et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endocrinol. Metab. 2000; 85: 1107–1113
- Wang W., Macapinlac H., Larson S. M., et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J. Clin. Endocrinol. Metab. 1999; 84: 2291–2302
- Kim J. H., Leeper R. D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987; 60: 2372–2375
- Koong S. S., Reynolds J. C., Movius E. G., et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 1999; 84: 912–926
- Short S. C., Suovuori A., Cook G., et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 2004; 16: 569–574
- Kohlfuerst S., Igerc I., Gallowitsch H. J., et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 2006; 16: 1113–1139
- Haugen B. R. Management of the patient with progressive radioiodine non-responsive disease. Semin. Surg. Oncol. 1999; 16: 34–41
- Ain K. B., Egorin M. J., DeSimone P. A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10: 587–594
- Shimoaka K., Schoenfeld D. A., DeWys W. D., et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56: 55–60
- NCCN clinical practice guidelines in oncology, http://www.nccn.org/
- Cooper D. S., Doherty G. M., Haugen B. R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16: 109–142
- Fagin J. A. The Jeremiah Metzger Lecture: Intelligent design of cancer therapy: trials and tribulations. Trans. Am. Clin. Climatol. Assoc. 2007; 118: 253–261
- Fagin J. A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 2004; 183: 249–256
- Wells S. A., Jr., Gosnell J. E., Gagel R. F., et al. Vandetanib in metastatic hereditary medullary cancer: follow-up results of an open-label phase II study. J. Clin. Oncol. 2007; 25: 303s, (Supplement) (abstract 6018)
- Gupta V., Puttaswamy K., Lassoued W., et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma
- Cohen E. E., Vokes E. E., Rosen L. S., et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J. Clin. Oncol. 2007; 303s, (abstract 6008) 25(Supplement)
- Sherman S. I., Schlumberger M. J., Droz J., et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J. Clin. Oncol. 2007; 301s, (abstract 6017), 25(Supplement)